{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"29.480","rs_stock_flag":false,"fiscal_year_end":"","hist_closedate":"","replication_method":null,"amt_os":"136,218,830","primaryexch":"HKEX","ric":"3378.HK","product_subtype":null,"db_updatetime":"23 Dec 2025 09:36","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":null,"inline_upper_strike_price":"","sedol":"BW9DKD6","am":"121.89","iv":"","ew_strike":"","as":"24.360","geographic_focus":null,"incorpin":"PRC","etp_baseCur":null,"ew_amt_os":"","bd":"24.340","registrar":"Tricor Investor Services Ltd.","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"100","update_time":"2025-12-23 01:36:34.0","lo52":"","shares_issued_date":"23 Dec 2025","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"Zhang Faming","underlying_ric":"3378.HK","hi52":"","issuer_name":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. - B - H Shares","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"23 Dec 2025 10:25","aum_date":"","lo":"23.000","mkt_cap":"3.31","f_aum_hkd":null,"ew_sub_per_to":"","ls":"24.360","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"Healthcare - Pharmaceuticals & Biotechnology","ew_desc":null,"inception_date":"","nc":"0","aum":"","issued_shares_class_B":null,"vo":"4.10","secondary_listing_flag":false,"listing_date":"23 Dec 2025","issued_shares_class_A":null,"as_at_label":"as at","ew_amt_os_dat":"","nm":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. - B - H Shares","nm_s":"HANXBIO-B","sym":"3378","inline_lower_strike_price":"","listing_category":"Primary Listing","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.020","strike_price":"","summary":"Hanx Biopharmaceuticals (Wuhan) Co Ltd is a China-based company mainly engaged in the discovery, development and commercialization of immuno-oncology therapy. The product pipeline mainly comprises clinical stage drug candidates focused on oncology, including HX009, HX301 and HX044, as well as preclinical stage drug candidates including antibody drug conjugate, bispecific antibody and monoclonal antibody for autoimmune and oncology market. The core product HX009 is a bifunctional anti-programmed death receptor 1 (PD-1) antibody signal-regulatory protein alpha (SIRPα) fusion protein developed in-house. HX301 is a multi-targeted kinase inhibitor. HX044 is a bifunctional anti- cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (SIRPα) fusion protein. The Company is also engaged in the operation of antibody technology platform VersatiBody and autoimmune disease therapeutic platform autoRx40. The Company mainly operates its businesses in the domestic market.","op":"28.900","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"Biotechnology","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"Bldg A8, Ph II, Bio-Inno Park<br/>No. 1 Jiufeng 1st Road<br/>East Lake New Tech Dev Zone<br/>Wuhan, Hubei, PRC","pc":"0.00","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":null,"hdr":false,"launch_date":"","hc":"","isin":"CNE100007C34","moneyness":""}},"qid":"1766457638428"}
